Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
ID00470327

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

Led by University of Chicago · Updated on 2025-05-14

4000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

U

University of Chicago

Lead Sponsor

I

Idiopathic Pulmonary Fibrosis Clinical Research Network

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying the natural progression of Interstitial Lung Disease (ILD) and related conditions such as Idiopathic Pulmonary Fibrosis, Sarcoidosis, and Connective Tissue Disorder. This observational study aims to collect data and blood samples from patients receiving care for ILD, as well as from a control group, to better understand the different expressions of these diseases. Participants include patients diagnosed with ILD and a control group without the disease. The study involves gathering data and blood samples during their care without any specific drug or treatment interventions. The observational nature means participants continue their usual medical care while contributing information to the research. During the study, researchers will monitor the natural history and course of ILD yearly through data collection and blood sampling. This includes tracking disease progression and characteristics over time. Participation involves regular assessments as part of routine clinical care, with no experimental treatments given. The study is sponsored by the University of Chicago and is ongoing through December 2030.

CONDITIONS

Brief Title

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of Interstitial Lung Disease
  • Age 18 years or older
Not Eligible

You will not qualify if you...

  • No diagnosis of Interstitial Lung Disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Long-term Monitoring

Duration - Up to 8 years

Participants are observed to understand the natural progression of Interstitial Lung Disease over time.

Yearly visits

Trial Site Locations

Total: 1 location

1

University of Chicago

Chicago, Illinois, United States, 60637

Actively Recruiting

Loading map...

Research Team

V

Vanita Patel, MPH

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Phase I, Single-center, Randomized, Double-blind, Single-d...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

1 location

An Open-label Extension Trial of the Long-term Safety and Ef...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

373 locations

A Randomized, Double-blind, Placebo-controlled, Single and M...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here